The Pharma Data

OCTOBER 21, 2020

21, 2020 — A combination of two “targeted” therapies can beat back a rare form of blood cancer — without the toxic effects of chemotherapy, a new study has found. 22 in the New England Journal of Medicine , could lead to an effective — and chemo-free — treatment for the cancer. WEDNESDAY, Oct.

Drugs 52

Drugs Genetics Trials Research 52

The Pharma Data

OCTOBER 21, 2020

21, 2020 — A combination of two “targeted” therapies can beat back a rare form of blood cancer — without the toxic effects of chemotherapy, a new study has found. 22 in the New England Journal of Medicine , could lead to an effective — and chemo-free — treatment for the cancer. WEDNESDAY, Oct.

Drugs 52

Drugs Genetics Trials Research 52

pharmaphorum

FEBRUARY 22, 2021

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. . million in Europe.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

The Pharma Data

AUGUST 18, 2020

The main focus of the deal is Dragonfly’s monovalent IL-12 immunoglobulin Fc fusion protein known as DF6002, which the company has been investigating in the treatment of both solid and blood cancers.

Sales 52

Sales Protein Drugs 52

pharmaphorum

AUGUST 18, 2022

bluebird bio’s Zynteglo has become the first cell-based gene therapy to be approved in the US, getting the nod from the FDA as a treatment for patients with beta thalassaemia who require regular blood transfusions. An FDA advisory committee recommended approval of Zynteglo on the strength of that data in June.

Gene Therapy 52

Gene Therapy FDA Approval Gene Clinical Trials 52

pharmaphorum

AUGUST 25, 2022

Tecvayli (teclistamab) has been approved by the European Commission for adults with the blood cancer whose disease has progressed have after at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, said J&J.

Antibody 94

Antibody Marketing Drugs Medicine 94

pharmaphorum

JANUARY 5, 2021

The FDA’s breakthrough status is for tiragolumab plus Tecentriq is the first for a TIGIT drug, and covers the first-line treatment of patients with advanced-stage non-small cell lung cancer (NSCLC) that expresses high levels of PD-L1. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Immune Response 52

Immune Response FDA Approval Drugs Sales 52

XTalks

JANUARY 28, 2022

Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose. Related: Cancer Blood Test Developed by University of Oxford Researchers Can Detect Metastasis. The company is expecting approval from the European Medicines Agency (EMA) soon as it prepares for a European launch in the second quarter of this year.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

pharmaphorum

JANUARY 11, 2021

While bluebird has conducted pioneering work in gene therapy for blood disorders and in cancer cell therapy, products have been delayed by issues with filing data for the FDA. million price tag. Leschly will also take the role of executive chair at bluebird, according to a company statement.

Gene Therapy 59

Gene Therapy Gene Genetic Disease Manufacturing 59

XTalks

FEBRUARY 27, 2024

Melanoma is a type of skin cancer often caused by exposure to ultraviolet light, such as that from sunlight or indoor tanning. Despite accounting for only about one percent of all skin cancers, melanomas make up a significant proportion of cancer-related deaths. The cost is the highest of any cell-based cancer drug in the US.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

pharmaphorum

DECEMBER 12, 2022

. “This is exciting news because existing treatments fail to improve platelet counts for as many as 30% of adults with chronic ITP,” commented said Catherine Broome of Georgetown Lombardi Cancer Centre in Washington DC, the trial’s lead investigator.

Sales 52

Sales Trials Drugs Antibody 52

pharmaphorum

NOVEMBER 19, 2020

But it has been a source of controversy – it works by attacking the rogue blood vessels that build up in the retina that are the root cause of wet AMD, something that Roche’s Avastin (bevacizumab) cancer drug can do in an off-label use at a fraction of the price.

FDA Approval 63

FDA Approval Marketing Drugs Clinical Development 63

pharmaphorum

JULY 25, 2022

The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for multiple myeloma , joining a growing group of BCMA-targeted therapies for the blood cancer.

Antibody 52

Antibody Medicine Drugs Trials 52

Delveinsight

FEBRUARY 9, 2021

Deerfield and Dana-Farber Establish Links in USD 130 Million Cancer Research Deal. Deerfield Management has entered into a research agreement with Dana-Farber Cancer Institute to fuel the development of therapeutics and diagnostics for cancer. Breyanzi, BMS’ Blood Cancer CAR-T Therapy Receives FDA Nod.

FDA Approval 52

FDA Approval Marketing Research Protein 52

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. With blood cancers, you inject the product, and the cells are there, and the target is there. We also have the challenge of delivery.

Gene Therapy 147

Gene Therapy Gene Engineer Production 147

XTalks

DECEMBER 21, 2022

In 2022, the US Food and Drug Administration (FDA) approved the following four new gene therapies: Adstiladrin (nadofaragene firadenovec-vncg) for the treatment of adult patients with high-risk Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

Life Science 52

Life Science Gene Therapy Gene Clinical Trials 52

XTalks

SEPTEMBER 27, 2022

The record-breaking price tag of Skysona is not surprising for one-time gene therapies like it. The price tag reflects “the clinical benefit [it] provides as an urgently needed treatment option to slow the progression of neurologic dysfunction in children impacted by progressive, irreversible and fatal rare disease,” Obenshain added.

FDA Approval 52

FDA Approval Gene Therapy Drugs Gene 52

XTalks

JANUARY 19, 2024

Radiobiological and Clinical Considerations from CRO and Emerging Biotech Radiopharmaceuticals are medicinal formulations containing radioisotopes that are used in the field of nuclear medicine primarily for the diagnosis and treatment of various diseases, particularly cancer.

DNA 66

DNA Radiology FDA Approval Development 66

XTalks

AUGUST 17, 2020

To learn more about innovations in the field, Xtalks spoke to Anish Suri, PhD, president and chief scientific officer of Cue Biopharma about the company’s initiatives in the development of immune-based biological compounds for the treatment of cancers and autoimmune diseases. Cell-Based Immunotherapy vs. Immune Biologics. asks Dr. Suri.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Drug Discovery World

OCTOBER 3, 2022

She coordinates the AI 4 Scientific Discovery Network and the Future Blood Testing Network, in addition to running an ethics working group. He is a Rhodes Scholar, an active member of several cancer research organisations and an elected member of the Young Academy of the German National Academy of Sciences & Sigma Xi.

Drugs 52

Drugs Scientist Bioinformatics Medicine 52

Delveinsight

DECEMBER 3, 2020

Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. Merck chooses TriNKET cancer immunotherapy program. Merck has snapped up Dragonfly’s TriNKET cancer immunotherapy program.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

Delveinsight

JULY 22, 2020

The IoT can provide real-time data of patient’s vital stats such as heart rate, blood pressure, temperature, body weight, oxygen saturation level, blood sugar, kidney functioning and many others. The hospital inventory is equipped with tagged sensors. What are the benefits of using IoT devices? Medical Equipment Tracking.

Doctors 59

Doctors Doctor Marketing Production 59

pharmaphorum

OCTOBER 4, 2022

In this article, Ben Hargreaves takes a look at the renewed effort to tackle deaths from cancer in the US through the Cancer Moonshot. Central to the initiative is the aim to gather data from willing participants that can provide greater insights into cancer development and treatment over time. Building a bank.

Biobanking 94

Biobanking Clinical Trials Clinical Trials Trials 94

pharmaphorum

FEBRUARY 26, 2021

The company has also faced claims that it did not adequately communicate the risks of its opioid painkillers in its marketing, contributing to the US’ ‘opioid epidemic’, and that its talc products could contain small amounts of asbestos and lead to cancer. But ultimately these dips are likely to only be blips on the radar for J&J.

Sales 116

Sales Production Pharma Companies Marketing 116

Pharma Marketing Network

JUNE 8, 2020

I mean, you know, there has obviously been a lot of breakthrough biologics and different therapeutics like around cancers and things like that, that have high price tags because maybe they don’t have as big a market as you know, something’s wrong, you know blood pressure medication.

HR 40

HR Marketing Doctors Doctor 40